An Open-label Study of CNTX 4975-05 in Osteoarthritis Knee Pain
Research type
Research Study
Full title
An Open-label, 8 Week Study to Compare the Comfort and Complexity of Five Treatment Regimens for CNTX 4975-05 Intra-articular Injection in Subjects with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain
IRAS ID
252536
Contact name
Philip Conaghan
Contact email
Sponsor organisation
Centrexion Therapeutics Corp
Eudract number
2018-003094-10
Clinicaltrials.gov Identifier
IND, 132,999
Duration of Study in the UK
1 years, 1 months, 0 days
Research summary
This study is being run for research purposes. The study drug, CNTX-4975-05, is being tested for the treatment of pain from osteoarthritis (OA) of the knee.
CNTX-4975-05 has not yet been approved by the FDA - it is an experimental treatment. The active ingredient in CNTX 4975-05 is purified capsaicin. Capsaicin is the substance in chili peppers that makes them taste hot.
This study is being conducted to learn how well CNTX 4975-05 reduces knee OA pain after it is injected into the knee joint. This study will evaluate the pain-relieving effects of CNTX 4975-05 and how different methods of cooling the knee before and after the injection might affect any pain-relieving effects.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
18/EM/0321
Date of REC Opinion
27 Nov 2018
REC opinion
Further Information Favourable Opinion